This study investigates KRAS mutant cancer. It evaluates the effects of an investigational medication that targets a specific mutation in the KRAS gene found in some cancers.
The study focuses on assessing the safety and preliminary antitumor activity of the investigational medication. It evaluates how the medication works alone and in combination with other treatments.
- Who can participate: Adults with locally advanced unresectable or metastatic solid tumors that have specific KRAS mutations may participate. Participants must have measurable disease and a good performance status.
- Study details: Participants will receive an investigational medication, which may be combined with other treatments. In some cases, a placebo may be used. An inactive substance that looks like the investigational medicine but does not contain any medicine.
How understandable was the trial content above?
Hard to understand
Easy to understand